AROA Biosurgery Limited specializes in regenerative healing products for soft-tissue repair. It emphasizes the use of extracellular matrix (ECM) biomaterials in its offerings, giving it a niche position in the medical devices market. The company aims to improve healing outcomes and reduce healthcare costs, standing out through its innovative solutions and successful commercialization strategies.
Track bearish sentiment and short interest over time
Historical Price Data
View stock price movements, volume, and trading patterns
Industry & Focus
regenerative medicine
medical devices
soft tissue repair
biotechnology
wound care
Company Overview
AI-generated company summary
AROA Biosurgery Limited specializes in regenerative healing products for soft-tissue repair. It emphasizes the use of extracellular matrix (ECM) biomaterials in its offerings, giving it a niche position in the medical devices market. The company aims to improve healing outcomes and reduce healthcare costs, standing out through its innovative solutions and successful commercialization strategies.
Company History
Founded in 2008, AROA Biosurgery Limited focused on developing regenerative healing products using proprietary ECM technology. The company achieved a significant milestone with its initial public offering on the ASX in July 2020. Over the years, AROA has expanded its product range and penetrated key international markets, emphasizing research and strategic partnerships.
Competitive Advantages
AROA's competitive advantages include its proprietary ECM biomaterial technology, which enables superior healing outcomes in soft tissue repair. The company also benefits from strong partnerships with global distribution networks, allowing for an expanded market reach. Additionally, its product differentiation in the wound care sector positions it uniquely against competitors.
Risk Factors
•Technological risk from advancements by competitors in regenerative medicine
•Regulatory changes affecting medical device approvals
•Dependence on a limited number of key distribution partnerships
Recent Developments
Last 6 months
In the last six months, AROA has reported significant financial growth in its latest earnings results, driven by an increase in international sales and successful product launches. The company has also announced a new partnership agreement to enhance its distribution channels globally.
Key People
Leadership team at Aroa Biosurgery
BW
Brian Ward
CEO
Brian Ward has extensive experience in the biotechnology sector, serving as CEO of AROA Biosurgery since its inception. He has a background in biomedical engineering and has been pivotal in the company’s commercial and international growth.
JA
James Agnew
CFO
James Agnew is the CFO of AROA Biosurgery, bringing a wealth of financial management expertise to the role. His previous work in corporate finance has helped strengthen AROA’s financial position and drive investor relations forward.
Financial Reports
32 reports available
Aroa Half Year Results Presentation
Half Year ResultsNov 25, 2025via asx_announcements
Appendix 4D and Half Year Report
Half Year ResultsNov 25, 2025via asx_announcements
September 2025 Quarterly Report and Appendix 4C
Quarterly ReportOct 16, 2025via asx_announcements
June 2025 Quarterly Report and Appendix 4C
Quarterly ReportJul 29, 2025via asx_announcements
Annual Report to Shareholders
Annual ReportJun 27, 2025via asx_announcements
FY25 Full Year Results Presentation
Full Year ResultsMay 29, 2025via asx_announcements
FY25 Appendix 4E and Full Year Results
Annual ResultsMay 29, 2025via asx_announcements
Notification of Full Year Results Webinar - New Date
Full Year ResultsMay 13, 2025via asx_announcements